About the book
Cancer is, and will be in the future, one of the major public health issues. In the recent years, we are facing revolutionary steps forward in cancer treatment which are resulting in better survival and life quality of the patients. The major innovation in the last few years was immunotherapy treatment, precisely anti PD-1, anti PD-L1 inhibitors and CTLA 4 inhibitors. These drugs changed the treatment and prolonged lives of many patients, mostly in melanoma, lung and renal cell carcinoma, but also in other cancer diseases as well. The development of these drugs is now in the focus of oncology. Together with immunotherapy, well-known tyrosine kinase inhibitors (TKI) are developing rapidly, with new generations of drugs being discovered with several new goals: to treat patients resistant to first or second generation of TKI, to enter the central nervous system better and to decrease side effects. Besides in systemic therapy, many improvements are encountered also in the field of radiotherapy with new techniques like stereotactic ablative ones or treatment with protons that are emerging as a new hope for cancer patients. All novelties, of course, would not be possible without good supportive and palliative care. The aim of this book is to describe current treatment options for cancer patients, together with supportive care, as well as to elucidate new emerging treatments which will change the treatment armamentarium in the next years.